<DOC>
	<DOCNO>NCT02200809</DOCNO>
	<brief_summary>Purpose investigator study determine short medium term histological cancer control focal therapy use MR-guided focal laser ablation therapy treatment localised prostate cancer .</brief_summary>
	<brief_title>MR-guided Focal Laser Ablation Prostate</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Newly diagnose biopsy proven prostate cancer Intermediate risk patient ( PSA &lt; = 20 ng/mL , Gleason â‰¤ 7 , T2b ) No previous treatment prostate cancer Cancer lesion locate least 1 cm away neurovascular bundle accord Multimodality MR image Signed informed consent patient Age 18 year old Signed screen form ( determine exclusion metal device/foreign bodies/claustrophobia ) Impossibility obtain valid informed consent Patients unable undergo MR imaging , include contraindication Contraindications MR guide focal laser therapy ( colitis ulcerosa , rectal pathology abdomino perineal resection ) Metallic hip implant metallic implant device distorts local magnetic field compromise quality MR imaging Patients evidence nodal metastatic disease Patients estimate Glomerular Filtration Ratio ( eGFR ) &lt; 40 mL/min/1.73 m2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MR-guided therapy</keyword>
	<keyword>Focal laser ablation</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>